Now using studies in mice, University of Maryland School of Medicine (UMSOM) researchers have identified the mechanism behind these structural birth defects, which they say is due to the neural tissue aging prematurely, halting its growth before it has made enough cells to finish forming the neural tube.
The study, published on June 30 in Science Advances, was conducted by the UMSOM Center for Birth Defects Research, led by Peixin Yang, PhD, Professor of Obstetrics, Gynecology and Reproductive Sciences, Director of the Center for Birth Defects Research, and Vice Chair of Research in the Department, and E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean of UMSOM.
“Although diabetes is a disease generally associated with an older population, the modern diabetes epidemic in young people is largely fueled by obesity and inactivity. At the same time, many aging-related diseases are impacted by diabetes, and we now know that high blood glucose seems to induce or enhance premature embryonic aging,” said Dr. Yang. “For many decades, our hypothesis was that premature aging, known as senescence, was occurring in the fetuses of mothers with diabetes, and was, in part, inducing these birth defects. It was only recently that we have had the tools and technology to be able to test our hypothesis.”
Finding the precise mechanism for how maternal diabetes leads to these and other kinds of birth defects in the fetus is the first step to identifying a way to prevent these abnormalities from occurring. In the study, the researchers were able to delay the aging process in the tissue by using a cancer drug, allowing the neural tube to fully form in mouse pups born from mice with mutations mimicking diabetes.
Their findings suggest that more specialized therapies could be developed to prevent miscarriages or birth defects in babies born from mothers with diabetes.
First, the research team showed that the neural tube tissue in 8-day old mouse pups from mothers with diabetes contained markers of premature aging. These markers were not found in pups from mothers that did not have diabetes. Researchers then found that the cells with premature aging markers secreted a flurry of other chemical signals that caused the neighboring cells to die.
Next, the researchers treated the mouse pups from mothers with diabetes with the cancer drug rapamycin, known to prevent the toxic chemical signals from being released by the prematurely aging cells. They found that mouse pups treated with rapamycin had neural tubes that were fully formed like those found in pups born from mothers without diabetes.
“This drug essentially made the senescent cells behave normally,” said Dr. Yang. Unfortunately, rapamycin affects too many other cell processes and can be toxic, so it would not be a viable treatment for preventing neural tube defects in human infants.
“Our next step is to see if birth defects of the heart and kidney found in fetuses born from mothers with diabetes are caused by the same senescence mechanism. If so, it would suggest that we can develop a single treatment more specialized to these developmental processes to prevent this spectrum of birth defects,” said Dean Reece. “As mothers with diabetes have children with five times the birth defect rate compared to the general population and incidence of diabetes is ever increasing, it is imperative that we develop ways to prevent disability and promote healthy births.”
Additional authors include Cheng Xu, PhD, Research Associate in the Department of Obstetrics, Gynecology and Reproductive Sciences; Wei-Bin Shen, PhD, Assistant Professor of Obstetrics, Gynecology and Reproductive Sciences and Christopher Harman, MD, the Sylvan Frieman, MD Endowed Professor and Chair in Obstetrics, Gynecology & Reproductive Sciences at UMSOM, along with Sunjay Kaushal of Ann & Robert H. Lurie Children’s Hospital of Chicago, and Hidetoshi Hasuwa of Keio University.
This research was supported by several grants funding by the National Institutes of Health and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (HD100195, R01HD102206, R01HD099843), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01DK083243, R01DK101972, R01DK103024), and National Heart, Lung, and Blood Institute (NHLBI) (R01HL131737, R01HL134368, R01HL139060).
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world — with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 student trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu